Meeting the UK demand for COVID19/SARS-CoV-2 vaccines via integrated manufacturing and supply chain optimisation

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:10 publications

Grant number: EP/V01479X/1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2021
  • Known Financial Commitments (USD)

    $546,015
  • Funder

    UK Research and Innovation (UKRI)
  • Principle Investigator

    Pending
  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    Imperial College London
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine logistics and supply chains and distribution strategies

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

We shall deliver a blueprint for simultaneously ramping up production and ensuring uninterrupted delivery of SARS-CoV-2 vaccines in the UK to manage and prevent subsequent waves of the pandemic. We shall assist decision-making of manufacturers, governments and stakeholders during SARS-CoV-2 vaccine manufacture and distribution to ensure increased vaccine availability particularly during early stages of manufacturing. The proposed work will consider the UK population in its entirety from the outset with respect to both the population stratification strategy, based on health, disease exposure and socio-environmental risks, and vaccine distribution networks throughout the country including remote communities. Through our involvement in the vaccine hubs funded by the Department of Health (EP/R013764/1 and EP/R013756/1), we have developed world-leading capabilities in vaccine manufacturing and supply chain modelling and optimisation. Early access to the vaccine development efforts by the Jenner Institute in Oxford and the Shattock group at Imperial, has enabled us to develop accurate manufacturing models that will underpin the proposed research. We have access to a remarkable network of key UK and international vaccine stakeholders (CEPI, IAVI), manufacturers (GSK), BIA (via CPI) and governmental bodies, such as the Department of Health who will provide feedback and datasets.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Strategic Planning of a Joint SARS-CoV-2 and Influenza Vaccination Campaign in the UK.

Optimisation-based modelling for explainable lead discovery in malaria.

Quality by Design for enabling RNA platform production processes.

Novel drug-target interactions via link prediction and network embedding.

Pandemic-response adenoviral vector and RNA vaccine manufacturing.

Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK.

Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases.